ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) Files An 8-K Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition.

On February 16, 2017, ANI Pharmaceuticals,Inc. (the Company or
ANI) issued a press release announcing that ANI will release its
fourth quarter and full year 2016 financial results and 2017
guidance on Thursday, March 2, 2017, before the opening of the
U.S. financial markets. The Company will host a conference call
with the investment community at 10:30am, Eastern Time on March
2, 2017. A copy of the press release is furnished as Exhibit99.1
to this report.

In accordance with General Instruction B.2. of Form8-K, the
information in this Current Report on Form8-K, including
Exhibit99.1, shall not be deemed to be filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, and shall not be incorporated by reference into any
registration statement or other document filed under the
Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such
filing.

Item 5.03. Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.

On February 15, 2017, the Board of Directors (the Board) of ANI
Pharmaceuticals, Inc. adopted an amendment to Article III,
Section 1 of the Companys Amended and Restated Bylaws (the
Bylaws) to provide for a majority vote standard for the election
of directors in uncontested director elections. In future
uncontested elections of directors, each director of the Company
will be elected by the affirmative majority of the votes cast. A
majority of the votes cast means that the number of votes cast
for a director nominee must exceed the number of votes cast
against in order for that director to be elected. Under the
Company’s previous Bylaw provisions, directors were elected by a
plurality of the votes present in person or represented by proxy
at the meeting and entitled to vote on the election of directors.
In contested elections, directors will continue to be elected by
the vote of a plurality of the shares present in person or by
proxy at the meeting and entitled to vote on the election of
directors.

Under the Bylaws as amended, and the Company’s Corporate
Governance Guidelines, as amended, following any uncontested
election, an incumbent director who does not receive the required
majority vote is required to promptly tender his or her
resignation. The Nominating and Corporate Governance Committee
will consider the resignation and make a recommendation to the
Board as to whether the resignation should be accepted.

The Board must act on the Nominating and Corporate Governance
Committees recommendation within 90 days following certification
of the stockholder vote. If the Board does not accept a directors
resignation, the director will continue to serve until the next
annual shareholders meeting or his or her successor is duly
elected and qualified or until the directors earlier death, other
resignation, or removal. In addition, the Board shall, within
four business days after reaching its decision, publicly disclose
the decision, including the reasons for not accepting a
resignation offer, if applicable, by a filing a Current Report on
Form 8-K with the Securities and Exchange Commission. If a
directors resignation is accepted or, in an uncontested election,
a nominee who is not an incumbent director is not elected, the
Board may fill the resulting vacancy by the vote of a majority of
the remaining directors, decrease the size of the Board or take
any other appropriate action it deems to be in the best interest
of the Company.

The Companys Amended and Restated Bylaws is filed as Exhibit to
3.1 to this Current Report on Form 8-K. A copy of the Company’s
Amended and Restated Corporate Governance Guidelines is available
on the investor relations section of the Company’s corporate
website, www.anipharmaceuticals.com.

Item 9.01. Financial Statements and Exhibits.

About ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its generic products include Esterified Estrogen with Methyltestosterone, Etodolac, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup, Nimodipine, Opium Tincture, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Lithobid, Reglan and Vancocin. It has over two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. Its two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet.

ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) Recent Trading Information

ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) closed its last trading session at with 140,813 shares trading hands.